SYN

SYNTHETIC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.5200
-0.0212
-3.92%
Opening 14:25 07/09 EDT
OPEN
0.5400
PREV CLOSE
0.5412
HIGH
0.5499
LOW
0.5200
VOLUME
56.94K
TURNOVER
--
52 WEEK HIGH
0.6400
52 WEEK LOW
0.2522
MARKET CAP
9.50M
P/E (TTM)
-0.5619
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SYN stock price target is 1.375 with a high estimate of 1.500 and a low estimate of 1.250.

EPS

SYN News

More
Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase
PR Newswire · 06/30 12:00
Synthetic Biologics Announces Submission Of IND Application To US FDA For SYN-020 Intestinal Alkaline Phosphatase
ROCKVILLE, Md., June 30, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat
Benzinga · 06/30 11:04
Edited Transcript of SYN.A earnings conference call or presentation 5-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 06/15 16:41
Synthetic Bio inks deal to advance development of candidate SYN-020
Synthetic Biologics (NYSEMKT:SYN) has entered into an agreement with Massachusetts General Hospital (MGH), granting the company an option for an exclusive
seekingalpha · 05/27 17:02
Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases
PR Newswire · 05/27 12:00
How Synthetic Biologics, Inc. (NYSEMKT:SYN) Can Impact Your Portfolio Volatility
Simply Wall St. · 05/06 14:55
Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/06 01:58
Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results
PR Newswire · 05/05 21:15

Industry

Biotechnology & Medical Research
-0.28%
Pharmaceuticals & Medical Research
-0.69%

Hot Stocks

Symbol
Price
%Change

About SYN

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
More

Webull offers kinds of Synthetic Biologics Inc stock information, including AMEX:SYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYN stock methods without spending real money on the virtual paper trading platform.